AXLA

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $7.00. The company's shares closed last Tuesday at $2.03. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 6.2% and a 40.4% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Arrowhead Pharmaceuticals, and Better Therapeutics, Inc. Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $10.25, representing a 407.4% upside.
https://www.tipranks.com/news/blurbs/axcella-health-axla-receives-a-buy-from-chardan-capital?utm_source=advfn.com&utm_medium=referral